FDA Accepts Supplemental Application for TYRUKO (Natalizumab-SZTN)
The FDA has accepted a supplemental application for TYRUKO, a biosimilar of natalizumab.
Asset / Drug
Drug and asset intelligence for TYRUKO with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.